Growing community of inventors

Lund, Sweden

Johan Evenäs

Average Co-Inventor Count = 4.88

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 5

Johan EvenäsThomas Brimert (3 patents)Johan EvenäsBerit Johansen (2 patents)Johan EvenäsGeorge Kokotos (2 patents)Johan EvenäsInger-Reidun Aukrust (2 patents)Johan EvenäsJoakim Larsson (2 patents)Johan EvenäsMarcel Sandberg (1 patent)Johan EvenäsGeir Kildahl-Andersen (4 patents)Johan EvenäsKlaus Dreisch (2 patents)Johan EvenäsKildahl-Andersen Geir (2 patents)Johan EvenäsMarcel Sanderberg (1 patent)Johan EvenäsMichael Rützler (1 patent)Johan EvenäsGeorge Kokotos (0 patent)Johan EvenäsJohan Evenäs (4 patents)Thomas BrimertThomas Brimert (9 patents)Berit JohansenBerit Johansen (19 patents)George KokotosGeorge Kokotos (11 patents)Inger-Reidun AukrustInger-Reidun Aukrust (7 patents)Joakim LarssonJoakim Larsson (4 patents)Marcel SandbergMarcel Sandberg (7 patents)Geir Kildahl-AndersenGeir Kildahl-Andersen (4 patents)Klaus DreischKlaus Dreisch (2 patents)Kildahl-Andersen GeirKildahl-Andersen Geir (2 patents)Marcel SanderbergMarcel Sanderberg (4 patents)Michael RützlerMichael Rützler (1 patent)George KokotosGeorge Kokotos (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Avexxin As (2 from 22 patents)

2. Apoglyx Ab (2 from 2 patents)


4 patents:

1. 10851114 - 2-oxothiatole compounds having activity as cPLAinhibitors for the treatment of inflammatory disorders and hyperproliferative disorders

2. 10730865 - Compounds for modulating aquaporins

3. 10150781 - 2-oxothiatole compounds having activity as CPLA2 inhibitors for the treatment of inflammatory disorders and hyperproliferative disorders

4. 10011597 - Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/7/2025
Loading…